Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Approximately 10% of all female Crohn's patients have a rectovaginal fistula. Rectovaginal
fistulas cause air, stool, and/or drainage per vagina and may be associated with pain,
recurrent urinary tract infections and diminished quality of life. Conventional therapy
includes immunosuppressive medications used to treat Crohn's disease and various surgical
interventions. However, all have limited ability to heal these fistulas. The purpose of this
study is to determine the safety and efficacy of using allogeneic bone marrow derived
mesenchymal stem cells (MSCs) to treat people with rectovaginal fistulas in the setting of
Crohn's disease.